Vesilute

Also known as: Vesilut, ED, Glu-Asp

Evidence: Anecdotal

PeptideLab is an educational platform for learning about peptides. The information here is for educational and research purposes only. It is not medical advice, diagnosis, or treatment, and PeptideLab does not claim to diagnose, treat, cure, or prevent any disease or health condition. Many peptides discussed have not been approved for human use by the FDA or other regulatory bodies. Consult a qualified healthcare professional before making any health-related decision.

Overview

Synthetic dipeptide ED (Glu-Asp), listed by its developers as Vesilut; it appears only in transporter docking studies, and no published study supports its bladder label.

The name implies a bladder peptide, but no published study tested ED on bladder tissue, urothelium or urinary function, and the developing group's own table gives no citation for the bladder label (Khavinson 2022). The old record stored KED, which is Vesugen; the developers list Vesilut as the dipeptide ED (Glu-Asp). The only indexed papers naming it are docking studies of peptide transport (Khavinson 2022, 2023). No animal, cell or human study has been published.

Benefits

No published biological effect in any model; transport by PEPT and LAT family carriers predicted by docking (in silico)

Dosing reference

Research dose: 200 to 1000 mcg daily: vendor/community range, no published human dose
Range: 200 to 1000 mcg, 1x daily

Sold as oral capsules and as lyophilized powder for injection. No published dose in any species. Community protocols run 10 to 20 day courses two or three times a year; no study compared schedules.

Mechanism

Unknown; no mechanism has been studied. Docking predicts the dipeptide can be carried by PEPT and LAT family transporters (Khavinson 2022, 2023). The old bladder, detrusor and urothelial claims had no source.

Evidence

Anecdotal: no peer-reviewed data

Listed as Vesilut (ED) in the developing group's table of peptide bioregulators, with no citation for its bladder label (Khavinson et al., 2022)
Docking predicted transport by PEPT and LAT family carriers (Khavinson et al., 2022)
Included among 26 ultrashort peptides docked to LAT and PEPT family transporters (Khavinson et al., 2023)
Human-trial status: none, and no animal or cell study has been published

References

Side effects

No safety data in any species; the compound has not been tested in cells, animals or people.

Storage

Storage: Room temperature
Lyophilized: 24+ months

Pharmacology

Half-life: No published pharmacokinetic data in any species
Bioavailability: Not measured in any species; docking only (Khavinson 2022, 2023)
Molecular weight: 262.22 Da
Sequence: ED (Glu-Asp)